A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy (SWITCH)

  • days left to enroll
  • participants needed
  • sponsor
Updated on 25 July 2022
replacement therapy
type 1 gaucher disease
velaglucerase alfa
substrate reduction therapy


The study will provide information on outcomes in people with type 1 Gaucher disease when they are treated with velaglucarase alfa (also called VPRIV), under standard care. Standard care means the participant will be treated according to the clinic's standard practice. The study sponsor will not be involved in how participants are treated with VPRIV, will provide instructions on how the clinic will record what happens during the study.

VPRIV is a type of enzyme replacement therapy (also known as ERT). Before starting the study, participants must either have switched from substrate reduction therapies (SRT) to VPRIV or switched from other enzyme replacement therapies to SRT then finally to VPRIV. During this time, medical data will be collected from the participants' medical records.

During the study, participants will be treated with VPRIV according to their clinic's standard practice. VPRIV is given by a slow injection into the vein, also known as an infusion. This will happen in the clinic or at home.

The study will record if blood levels of specific substances remain stable or improve during the switch to treatment with VPRIV. Some of these substances will show if organs such as the liver or spleen are working well. Others are blood cells that help blood to clot, known as platelets. Another is a substance in a red blood cell used to carry oxygen around the body, known as hemoglobin.

Participants will use a digital tool so they can be more involved in decision making in their treatment. The digital tool is a mobile phone app, in which each participant can log their daily activities, their general health and wellbeing, and other key information.

Medical data will also be collected from the participants' charts during this time.

Health problems of the participants will be recorded during the study to check if there were any side effects from VPRIV treatment.

Participants will be in this study for up to 12 months.

Condition Gaucher Disease
Treatment No intervention, Velaglucerase alfa, Digital Engagement Application (GD App)
Clinical Study IdentifierNCT04718779
Last Modified on25 July 2022


Yes No Not Sure

Inclusion Criteria

Participant eligibility is determined according to the following criteria prior to entry
into the study
In the opinion of the investigator, the participant is capable of understanding and
complying with protocol requirements
Participant either signs and dates a written, informed consent form or completes an
e-consent process prior to the initiation of any study procedures
Participant has been diagnosed with GD type I; diagnosis was confirmed biochemically
Participant is aged 18 or older
and/or genetically
Participant has been treated with SRT for at least 3 months prior to switch to VPRIV
Participant has been treated with VPRIV at least 3 months prior to enrollment
(Baseline [Day 0])
Arm A: Participant is able to use mobile application based on clinician's judgment
(e.g., owns an iPhone version 5 or later or smartphones with Android operating
systems, have an active data plan or regular Wi-Fi access)
Arm A: The participant's primary language is English

Exclusion Criteria

Participant is judged by the investigator as being ineligible for any other reason
Participant has L444P/L444P GBA1 genotype (c.1448T greater than [>] C)
Any participant who meets any of the following criteria will not qualify for entry into the
Participant is an immediate family member, study site employee, or is in a dependent
relationship with a study site employee who is involved in conduct of this study
(e.g., spouse, parent, child, sibling) or may consent under duress
Participant has Parkinson's disease, a history of central nervous system [CNS]
manifestations, or any other neurological disorder (e.g. Lewy Body Disease
Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple sclerosis)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note